GlassScriptPhysician profile
Joel M Rice
NPI 1013048800
$693.76
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.53 · 2023: $93.30 · 2024: $325 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $29.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.25 |
| Education | $29.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $144.91 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $106.83 | 2023-2025 | Tecentriq, Alecensa, Phesgo |
| Jazz Pharmaceuticals INC. | $100.63 | 2022-2025 | |
| Gilead Sciences, INC. | $73.16 | 2024-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $48.13 | 2023-2025 | Lynparza |
| Adaptive Biotechnologies Corporation | $41.56 | 2024 | Clonoseq |
| Lilly USA, LLC | $28.77 | 2025 | Jaypirca, Verzenio |
| Tempus Ai, INC | $28.75 | 2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $24.75 | 2024 | Alunbrig |
| Astellas Pharma US INC | $17.69 | 2024 | Veozah |
| Stemline Therapeutics INC. | $17.00 | 2025 | Orserdu |
| Eisai INC. | $16.90 | 2024 | |
| Pharmaand Gmbh | $15.80 | 2025 | Rubraca |
| Tolmar, INC. | $15.80 | 2025 | Rubraca |
| Regeneron Healthcare Solutions, INC. | $13.08 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.